- Home
- WOW vs GLUE Comparison
WOW vs GLUE Comparison
Compare WOW & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOW
- GLUE
- Stock Information
- Founded
- WOW 2001
- GLUE 2019
- Country
- WOW United States
- GLUE United States
- Employees
- WOW N/A
- GLUE N/A
- Industry
- WOW Cable & Other Pay Television Services
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- WOW Telecommunications
- GLUE Health Care
- Exchange
- WOW Nasdaq
- GLUE Nasdaq
- Market Cap
- WOW 285.5M
- GLUE 351.2M
- IPO Year
- WOW 2017
- GLUE 2021
- Fundamental
- Price
- WOW $5.09
- GLUE $4.80
- Analyst Decision
- WOW Hold
- GLUE Buy
- Analyst Count
- WOW 2
- GLUE 2
- Target Price
- WOW $5.20
- GLUE $13.50
- AVG Volume (30 Days)
- WOW 3.4M
- GLUE 369.2K
- Earning Date
- WOW 08-11-2025
- GLUE 08-07-2025
- Dividend Yield
- WOW N/A
- GLUE N/A
- EPS Growth
- WOW N/A
- GLUE N/A
- EPS
- WOW N/A
- GLUE 0.29
- Revenue
- WOW $604,800,000.00
- GLUE $177,986,000.00
- Revenue This Year
- WOW N/A
- GLUE $83.76
- Revenue Next Year
- WOW N/A
- GLUE N/A
- P/E Ratio
- WOW N/A
- GLUE $16.32
- Revenue Growth
- WOW N/A
- GLUE 2990.57
- 52 Week Low
- WOW $3.06
- GLUE $3.50
- 52 Week High
- WOW $5.79
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- WOW 77.52
- GLUE 51.69
- Support Level
- WOW $5.06
- GLUE $4.54
- Resistance Level
- WOW $5.12
- GLUE $4.93
- Average True Range (ATR)
- WOW 0.03
- GLUE 0.21
- MACD
- WOW 0.03
- GLUE 0.06
- Stochastic Oscillator
- WOW 70.00
- GLUE 81.43
About WOW WideOpenWest Inc.
WideOpenWest Inc is a cable operator and broadband service, provider. The company serves residential, business and wholesale customers in Illinois, Michigan, Indiana, Ohio, Kansas, Tennessee, Maryland, and South Carolina. Its service portfolio consists of high-speed internet, data, voice, cloud, and cable television services. The company operates in one business segment that is Broadband Services. The majority of the revenue is generated from the subscription service revenue received.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.